Mefloquine: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
{ | __NOTOC__ | ||
{{Mefloquine}} | |||
{{CMG}}; {{AE}} {{chetan}} | |||
==Overview== | |||
'''Mefloquine''' hydrochloride (Lariam, Mephaquin or Mefliam) is an orally administered [[antimalarial drug|medication]] used in the prevention and treatment of [[malaria]]. Mefloquine was developed in the 1970s at the [[United States Department of Defense]]'s [[Walter Reed Army Institute of Research]] as a synthetic analogue of [[quinine]]. The brand name drug, Lariam, is manufactured by the Swiss company [[Hoffmann–La Roche]]. In August 2009, Roche stopped marketing Lariam in the United States. Generic mefloquine from other manufacturers is still widely available. Rare but serious neuropsychiatric problems have been associated with its use.<ref name=":0">Thomas, Katie. "F. D. A. Strengthens Warnings on Lariam, an Anti-Malarial Drug." ''The New York Times''. July 29, 2013.</ref> | |||
==Category== | |||
Antimalarial | |||
==US Brand Names== | |||
MEFLOQUINE HYDROCHLORIDE<sup>®</sup> | |||
==FDA Package Insert== | |||
''' [[Mefloquine description|Description]]''' | |||
'''| [[Mefloquine clinical pharmacology|Clinical Pharmacology]]''' | |||
'''| [[Mefloquine microbiology|Microbiology]]''' | |||
'''| [[Mefloquine indications and usage|Indications and Usage]]''' | |||
'''| [[Mefloquine contraindications|Contraindications]]''' | |||
'''| [[Mefloquine warnings and precautions|Warnings and Precautions]]''' | |||
'''| [[Mefloquine adverse reactions|Adverse Reactions]]''' | |||
'''| [[Mefloquine drug interactions|Drug Interactions]]''' | |||
'''| [[Mefloquine overdosage|Overdosage]]''' | |||
'''| [[Mefloquine clinical studies|Clinical Studies]]''' | |||
| | '''| [[Mefloquine dosage and administration|Dosage and Administration]]''' | ||
'''| [[Mefloquine how supplied|How Supplied]]''' | |||
'''| [[Mefloquine labels and packages|Labels and Packages]]''' | |||
==Mechanism of Action== | |||
The exact mechanism of action is uncertain. However, it is proposed to share a similar mechanism of action with chloroquine, which is inhibition of heme polymerase. | |||
|} | ==References== | ||
{{Reflist|2}} | |||
[[Category:Antibiotics]] | |||
[[Category:Wikinfect]] | |||
Revision as of 00:55, 8 January 2014
| Mefloquine |
|---|
| MEFLOQUINE HYDROCHLORIDE® FDA Package Insert |
| Description |
| Clinical Pharmacology |
| Microbiology |
| Indications and Usage |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Drug Interactions |
| Overdosage |
| Dosage and Administration |
| How Supplied |
| Labels and Packages |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Overview
Mefloquine hydrochloride (Lariam, Mephaquin or Mefliam) is an orally administered medication used in the prevention and treatment of malaria. Mefloquine was developed in the 1970s at the United States Department of Defense's Walter Reed Army Institute of Research as a synthetic analogue of quinine. The brand name drug, Lariam, is manufactured by the Swiss company Hoffmann–La Roche. In August 2009, Roche stopped marketing Lariam in the United States. Generic mefloquine from other manufacturers is still widely available. Rare but serious neuropsychiatric problems have been associated with its use.[1]
Category
Antimalarial
US Brand Names
MEFLOQUINE HYDROCHLORIDE®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
The exact mechanism of action is uncertain. However, it is proposed to share a similar mechanism of action with chloroquine, which is inhibition of heme polymerase.
References
- ↑ Thomas, Katie. "F. D. A. Strengthens Warnings on Lariam, an Anti-Malarial Drug." The New York Times. July 29, 2013.